Biobanking, genetic research for medical and scientific applications. Regenerative medicine services based on cell technologies.
We provide biobanking, genetic research, and regenerative medicine services for private and corporate clients.
Prevention of blood diseases
Umbilical cord blood contains hematopoietic stem cells (HSCs). They are the source of all hematopoietic and immune system cells, as well as some other types of cells.
If a person’s immune and hematopoietic cells are severely damaged, HSC transplantation can help restore and “reboot” the patient’s entire hematopoietic and immune system.
HSC transplantation is used to treat oncohematological diseases (leukemia), blood diseases (e.g., various types of anemia), and immune system diseases, as well as certain hereditary diseases. In addition, HSCs are being actively implemented in regenerative medicine for the treatment of cerebral palsy, autism, stroke, and many other diseases.
Prevention of blood diseases
After a baby is born and the umbilical cord is cut, umbilical cord tissue can be collected and mesenchymal stem cells (MSCs) can be isolated from it to be stored in the Gemabank cryogenic storage facility along with a piece of the tissue for future use.
The organ MSCs can transform into muscle, nerve, bone, fat, or liver cells.
They are being actively studied by scientists in clinical trials for use in the treatment of regenerative diseases, namely for recovery after injuries, treating heart diseases, liver diseases, arthrosis, ovarian dysfunction syndrome, psoriasis, multiple sclerosis, renal failure, spinal cord pathologies, autism, and many other diseases.
In this case, stem cells are suitable for both the child and his/her relatives.
Neonatal screening
Hemascreen for neonatal genetic screening for the 19 most common curable genetic diseases. An advanced screening option for 375 genetic diseases is also available.
Services for medical centers on the use of medical technology of autologous dermal fibroblasts for the correction of age-related and scarring skin defects
Cellular skin correction
Innovative proprietary medical technology of using one’s own dermal fibroblasts to correct age-related and scar skin defects.
Synthesizing collagen, elastin, hyaluronic acid, and other components of the intercellular matrix, fibroblasts effectively restore the microstructure of the skin and stimulate the natural processes of its renewal.
Skin condition diagnosis
Unique personalized diagnostics of the regenerative and proliferative potential of the fibroblast population in the patient’s skin. Modern laboratory techniques make it possible to assess the quantity and morphology of the fibroblasts available in the skin, as well as their functional division ability.
An individual program is created for the patient to correct defects and prevent skin aging, also using cell therapy.
Restoration of periodontal tissues
Innovative medical technology for the restoration of soft periodontal tissues using autologous gingival dermal fibroblasts.
Rendering services on genetic research and bioinformatics analysis for medical and scientific organisations.
Diagnosis of hereditary diseases
Genetico’s developments focus on socially significant diseases and reproductive medicine: DNA (genome, exome) research for the purpose of personalized diagnosis specification, risk assessment for future children, and selection of an effective therapy.
Genetico implements advanced genetic analysis technologies (Next Generation Sequencing, NGS): whole-genome and whole-exome research, as well as develops its own NGS panels for diagnosing and preventing hereditary diseases based on whole-exome sequencing, making modern technologies more accessible to patients, and the time of diagnosing hereditary diseases shorter. This means that therapy for curable diseases can be started earlier, which is critical for a number of conditions.
Targeted therapy for tumors
Tumor genomic profiling provides information about mutations associated with the response to target therapy or disease prognosis. It can help select the most effective therapy taking into account genetic properties of the patient’s tumor. This study includes only genes of confirmed clinical significance for prescribing target therapy, diagnosis specification, or prognosis.
Based on the tumor genomic profiling, the patient and their attending physician receive a report on clinically significant mutations identified in the tumor, a list of target drugs the response to which is associated with these mutations.
Screening for fetal chromosomal abnormalities
Non-invasive prenatal testing (NIPT) can determine the risk of major chromosomal pathologies of the fetus.
As the placenta grows, some of its cells are destroyed and small fragments of fetal DNA enter the mother’s bloodstream. This DNA is called cell-free fetal DNA or cfDNA. A pregnant woman’s blood contains her own cfDNA fragments and those from the fetus. Accurate fetal cell-free DNA analysis is possible as early as the 10th full obstetric week of pregnancy.
Prenetix is one of the most well-studied non-invasive prenatal tests (more than 268,000 women tested). The method’s sensitivity (correctly identified pregnancies with pathology) is up to 99.3%, the false positive rate is less than 0.04%.
Diagnosis of hereditary and oncologic diseases
Our services include bioinformatics pipelines for processing NGS data, approaches to sequencing data interpretation developed by Genetico, and software for interpreting NGS data.
Genetico has accumulated unique competencies in the analysis and clinical interpretation of NGS data by conducting a total of over 8,000 similar studies in the Russian population. Genetico has created an internal database of genetic variants, as well as software for interpreting NGS data using this database.
Improving IVF outcomes for pregnancy outcomes
Preimplantation genetic testing (PGT) is a method for analyzing the genetic status of an embryo before it is transferred into the uterine cavity as part of an IVF protocol.
A genetic status analysis may differ depending on the family’s medical goal. It can be a chromosomal analysis, testing for monogenic disorders.
PGT for chromosomal abnormalities (PGT-A) helps select embryos without chromosomal abnormalities within the resolution of the method. This can increase the effectiveness of an IVF cycle significantly, reduce the probability of having a child with chromosomal abnormalities and the risk of spontaneous abortions (pregnancy loss). Since the beginning of its work, Genetico has diagnosed more than 45,000 samples.
PGT-M allows for effective prevention of an embryo inheriting a monogenic disorder. The toolkit used by Genetico’s genetic laboratory is suitable for PGT of most known monogenic diseases, including:
At Genetico’s laboratory, PGT-M is performed for all hereditary monogenic disorders. The testing accuracy is 99.5%.
Services for IVF centers, families, and patients in the selection and provision of donor reproductive cells, services for personal storage and transportation of reproductive cells and tissues around the world.
Infertility treatment
Reprobank’s catalog contains more than 170 sperm donors of different ethnic origins. Since 2014, Reprobank has implemented extensive molecular genetic screening of its donors. Currently, to minimize the risk of transmitting hereditary diseases, sperm donors undergo whole exome genome sequencing. In addition to the mandatory medical examination, Reprobank’s sperm donors undergo an interview with a psychologist and consultation with a geneticist, which includes family history.
Reprobank limits the distribution of donor material by the number of families (no more than 30 families in case of birth of one or more children).
For each donor, Reprobank provides detailed information for recipients: photographs of donors as children, a psychological portrait, information about their relatives, etc.
Infertility treatment
Reprobank’s catalog contains more than 150 egg donors. Oocyte donors are tested for 54 most common monogenic mutations they may carry. This panel includes diseases with severe symptoms and high mortality.
Reprobank guarantees strict cell quality control. Our donors undergo continuous health monitoring and are punctured no more than once every three months. We keep records and control the use of eggs from each donor.
Reprobank limits the distribution of donor material by the number of families (no more than 30 families in case of birth of one or more children).
The bank provides detailed information for each donor: medical examination results, family history, personal characteristics, photographs of donors as children, voice recordings, etc.
Infertility prevention
Our own laboratory equipped in accordance with international standards. A unique labeling system and double control at each stage of biomaterial cryopreservation and storage. The material is stored in liquid nitrogen vapor, which prevents contamination and mechanical damage to the biomaterial.
Automated cryogenic storage: automatic nitrogen supply, round-the-clock temperature, pressure, liquid nitrogen level monitoring, video surveillance, and access control. The cryogenic storage facility can operate autonomously for 3 weeks: without electricity or nitrogen refills.
Infertility prevention
Our own laboratory equipped in accordance with international standards. A unique labeling system and double control at each stage of biomaterial cryopreservation and storage. The material is stored in liquid nitrogen vapor, which prevents contamination and mechanical damage to the biomaterial.
Automated cryogenic storage: automatic nitrogen supply, round-the-clock temperature, pressure, liquid nitrogen level monitoring, video surveillance, and access control. The cryogenic storage facility can operate autonomously for 3 weeks: without electricity or nitrogen refills.
Prevention of hereditary diseases